Now I have enough to write a comprehensive, well-sourced earnings preview.I have sufficient information now. Let me write the earnings preview.# Gilead Sciences (GILD) — Q2 2026 Earnings Preview Report Date: Tuesday, August 4, 2026, after market close | Call: 2026Q2 Earnings Call
GILD shares have been range-bound in the $124–$136 band since the Q1 report in early May, closing at $131.18 on 8/3/2026, roughly flat over the past month but still up meaningfully year-to-date. Options markets are pricing a relatively modest ~4.3% implied move for the report. Consensus sentiment is constructive but not euphoric: Wall Street's average price target sits in the high-$150s to ~$159, implying meaningful upside from current levels, and the stock carries a broadly bullish skew among covering analysts, even though the nearest-term rating consensus is more mixed (Hold-leaning on some models) given the messy GAAP EPS picture this year.
Headline optics on EPS will look ugly and should be ignored/looked-through by investors — more on that below.
Q1 2026 set an upbeat tone that should carry into Q2. In Q1, total revenue rose 4% to $7.0 billion, with product sales excluding Veklury up 8% to $6.8 billion, HIV sales up 10% to $5.0 billion, and Biktarvy up 7% to $3.4 billion. Management raised full-year base-business revenue guidance to $29.4–$29.8 billion (from $29.0–$29.4 billion) and full-year total product sales guidance to $30.0–$30.4 billion.
Yeztugo (lenacapavir for PrEP) is the single most important swing factor. After posting $166 million in Q1 (up 72% sequentially, beating expectations), management raised the 2026 Yeztugo sales guide to ~$1 billion, calling out ~95% payer coverage with $0 co-pay for most patients, leadership share in the injectable switch segment, and encouraging early persistency signals. Investors should watch for continued sequential acceleration and updated commentary on naive-patient uptake, DTC campaign impact (launched late February, with 6–12 month lag to full effect), and second/third-injection persistency data.
HIV overall should keep growing at a high-single-digit clip — management guided full-year HIV growth to ~8% (up from 6% previously), net of an estimated ~2% headwind from the Medicaid pricing agreement and ACA-subsidy changes. Biktarvy continues to hold >52% U.S. market share with no loss of exclusivity until 2036, a durability underappreciated by bears focused on pipeline competition.
The biggest incremental news since the Q1 print is that Trodelvy received FDA approval on June 24, 2026 for first-line metastatic triple-negative breast cancer (both as monotherapy in PD-L1-negative patients and in combination with Keytruda in PD-L1-positive patients) — broadening its label beyond the narrower approval competitor Datroway (AstraZeneca/Daiichi Sankyo) had received about a month earlier. Trodelvy already carried NCCN Category 1 recommendations ahead of approval and was described by management as the leading ADC in second-line mTNBC, up 37% year-over-year in Q1 on demand strength. Investors should look for early launch commentary on first-line uptake and any updated Trodelvy guidance, along with news on the pending EU approval decision and progress in EVOKE-03 (first-line NSCLC) and ASCENT-GYN (endometrial cancer), both expected to read out in H2 2026.
Cell therapy (Yescarta/Tecartus) remains the soft spot — Q1 sales fell 12% year-over-year on in- and out-of-class competition, and this pressure likely persisted into Q2. The offset is anito-cel: Gilead closed its $7.8 billion Arcellx acquisition on April 28, and the BLA for anito-cel in 4L+ relapsed/refractory multiple myeloma is under priority review with a PDUFA date of December 23, 2026. Management has guided that anito-cel revenue should begin in early 2027, so Q2 numbers will still reflect the base cell therapy competitive drag, but expect updated enrollment/launch-prep commentary on the $3.5 billion 4L+ CAR-T opportunity.
Gilead has been unusually acquisitive in 2026, closing three deals in quick succession: - Arcellx ($7.8B, closed April 28) — anito-cel and the D-domain BCMA binder platform - Ouro Medicines (~$1.675–2.2B upfront, split with Galapagos, closed early June) — gamgertamig, a BCMAxCD3 T-cell engager for autoimmune disease - Tubulis (up to ~$5B, closed May 22) — TUB-040, a NaPi2b-ADC in Phase 1b/2 for ovarian cancer/NSCLC, plus a next-gen ADC platform
These deals drove the $11.5 billion acquired IPR&D charge and associated financing costs that management said would cut full-year non-GAAP EPS guidance by ~$9.50/share, taking full-year non-GAAP EPS guidance to $(1.05)–$(0.65) (from $8.45–$8.85 previously) even as the underlying (ex-deal) EPS outlook was essentially maintained, thanks to the $400 million revenue guidance raise offsetting the incremental R&D/SG&A drag. The key thing for investors to reconcile on the call: how much of Q2's R&D/SG&A increase is deal-related (already guided as "modest and manageable") versus underlying investment (e.g., virology manufacturing, Yeztugo commercialization spend), and whether management reiterates that margins should still expand over time despite three deals running through integration simultaneously.
Watch for: - Confirmation that all three deals have now fully closed and are reflected in reported financials - Any update on capital allocation — Gilead returned >$1.4 billion to shareholders in Q1 (including $419M buybacks) and management signaled it's "less likely to pursue more sizable M&A this year," focusing instead on integration - Free cash flow trends (Q1 FCF was $2.4 billion, up from $1.65 billion a year earlier)
The headline GAAP/non-GAAP EPS loss investors will see Tuesday is a function of one-time acquisition accounting, not operating deterioration — the underlying base business (ex-Veklury) has been growing at a high-single-digit clip, HIV franchise durability looks intact through 2036, Yeztugo is tracking toward blockbuster status in year one, and Trodelvy just landed a major label expansion. The debate for the stock is less about this quarter's print and more about (1) whether Yeztugo's growth trajectory continues to surprise to the upside, (2) how quickly the newly acquired oncology/inflammation assets (anito-cel, TUB-040, gamgertamig) can begin contributing post-2026, and (3) execution on the imminent BIC/LEN launch just weeks away.